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ImmunogenicityAn ideal oral drug carrier should facilitate drug delivery to the gastrointestinal tract and its absorption into the sys-
temic circulation. To meet these requirements, we developed a thiomer-coated liposomal delivery system com-
posed of 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) and a maleimide-functionalized lipid, to which
chitosan-thioglycolic acid (CS-TGA) was covalently coupled. In addition to conventional 77 kDa CS-TGA
(CS-TGA77), we tested the 150 kDa homologue (CS-TGA150) as well as an S-protected version of this polymer
(CS-TGA150-MNA), inwhich someof the free SH-groups are conjugatedwith 6-mercaptonicotinamide to protect
them from oxidation. Coupling of CS-TGA to the liposomal surface led to an increase in the particle size of at least
150 nm and an increase in the zeta potential from approximately −33 mV to a maximum of about +36 mV,
depending on the polymer. As revealed by ﬂuorescence dequenching the formulations have a storage stability
of at least two weeks without releasing any encapsulated compounds. In simulated gastric ﬂuid, the system
was shown to be stable over 24 h, while in simulated intestinal ﬂuid, a slow, sustained release of encapsulated
compoundswas observed. According to our experiments, thiomer-coated liposomes didnot induce immunogenic
reactions after an oral administration to mice. To evaluate the permeation enhancing and efﬂux pump inhibiting
properties of CS-TGA coated liposomes we monitored the transport of ﬂuoresceinisothiocyanate-dextran
(FD4) and rhodamine-123 (Rho-123), respectively, through rat small intestine. Permeation studies showed a
2.8-fold higher permeation of FD4 in the presence of CS-TGA77 coated liposomes and an even 4-fold higher
permeation in the presence of CSA-TGA150-MNA coated liposomes. The latter also performed best when we
evaluated P-glycoprotein inhibiting properties by monitoring the transport of Rho-123, revealing a 4.2-fold en-
hancement respective to the buffer control. Taken together, thiomer-coated liposomeswere shown to protect en-
capsulated drugs in the stomach, slowly release them in the small intestine and enhance their absorption through
the intestinal tissue by opening tight junctions and inhibiting efﬂux pumps.
© 2012 Elsevier B.V. Open access under CC BY-NC-ND license. , Medical University of Graz,
316 4120305; fax: +43 361
radauer),
onach@oeaw.ac.at (C. Vonach),
n.ac.at (I. Pali-Schöll),
n-jarolim@meduniwien.ac.at
kop-Schnürch),
-ND license. 1. Introduction
The oral delivery of drugs is generally the most convenient route,
as it allows for painless and easy administration, and therefore high
patient compliance. However, many drugs cannot be administered
orally due to the harsh environment and/or low absorption from gas-
trointestinal (GI) tract. An optimal oral delivery system should there-
fore (1) protect compounds from degradation and (2) improve their
permeation through GI-barriers; enhancing their oral bioavailability.
Different nanoparticulate systems have been developed for the pro-
tection of drugs during gastrointestinal transit — among them, lipo-
somes. Despite several successful studies [1,2], however, liposomes
208 K. Gradauer et al. / Journal of Controlled Release 165 (2013) 207–215
N
A
N
O
M
E
D
IC
IN
Ehave not yet reached their full potential as oral drug carriers, though
in recent years several strategies have been developed to enhance the
stability of liposomes and improve their properties for oral delivery—
one of which is coating them with multifunctional polymers such as
chitosan, Carbopol®, Eudragit® or silica [3–6]. Following this concept,
we have recently generated liposomes coated with thiolated chitosan
(CS-TGA) [7].
Different thiolated polymers – designated thiomers – have been
previously designed, which commonly consist of SH-group-bearing
agents anchored to polymeric backbones. Thiomers have also been
shown to exhibit several promising properties for drug delivery, in-
cluding mucoadhesion; permeation enhancement; efﬂux pump inhi-
bition; and enzyme inhibition [8–11]. Despite these effects being
well-established for thiomers themselves, it remained questionable
as to whether thiomer-coated liposomes will still exhibit permeation
enhancing and efﬂux pump inhibiting properties, given that the
mucus layer lining the small intestine functions as a barrier refractive
to access by larger particles. To address this question, liposomes were
prepared by utilizing what was expected to be a more stable compo-
sition by comparison with those used in our previous study [7]. These
newly designed liposomes were evaluated in the context of their
storage stability, release kinetics, permeation enhancing and efﬂux
pump inhibitory properties, as well as regarding their immunogenic
behavior. To achieve even higher permeation enhancing and efﬂux
pump inhibitory properties, liposomes were coated with ‘S-protected
thiomers’, as this new type of thiomers is stable towards oxidation
[12].
2. Materials and methods
2.1. Materials
1,2-Dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) and 1,2-
dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-[4-(p-maleimido-
methyl) cyclohexane-carboxamide] (DPPE-MCC) were purchased from
Avanti Polar Lipids (Alabaster, AL). Chitosan-thioglycolic acid of two
different molecular weights (CS-TGA77; molecular weight: 77 kDa,
550 μmol SH-groups/g polymer and CS-TGA150; molecular weight:
150 kDa, 660 μmol SH-groups/g polymer) and the chitosan-thioglycolic
acid 6-mercaptonicotinamide-conjugate (CS-TGA150-MNA; molecular
weight: 150 kDa, 380 μmol S-protected thiol groups and 280 μmol free
SH-groups/g polymer)were synthesized according tomethods described
previously [12,13]. Fluoresceinisothiocyanate-dextran (FD4, 4400 Da)
was supplied from TdB Consultanca AB (Uppsala, Sweden). All other
chemicals were of reagent grade or of the best grade available and pur-
chased from Sigma-Aldrich (Vienna, Austria).
2.2. Preparation of liposomes
Liposomes were prepared by thin lipid ﬁlm rehydration method.
Brieﬂy, DPPC and the maleimide-functionalized lipid DPPE-MCC
were dissolved in methanol and mixed in a molar ratio of 3:0.3. The
organic solvent was evaporated under a nitrogen stream, and the
resulting lipid ﬁlm was dried overnight in a vacuum chamber. A
10 mM phosphate buffer containing 150 mM NaCl, pH 7.4 (PBS)
was added to the dry lipid ﬁlm, which was then rehydrated for 1 h
at a temperature of 50 °C with repeated vortexing. The so-formed
multilamellar vesicles (ﬁnal lipid concentration: 30 mg/mL) were
sized by freeze and thaw and size extrusion through 200 nm polycar-
bonate membranes (Whatman Inc., Clifton, NJ) with a mini-extruder
(Avanti Polar Lipids, Alabaster, AL).
To evaluate particle stability and release behavior, the ﬂuorophore/
quencher couple 8-aminonaphthalene-1,3,6-trisulfonic acid (ANTS)/
p-xylene-bis-pyridinium bromide (DPX) was encapsulated within the
liposome during the hydration step. Brieﬂy, 5.4 mg/mL ANTS and
19 mg/mL DPX were solved in PBS and added to the lipid ﬁlm. Allfurther steps were carried out as described above. After size extrusion,
free ANTS/DPX was separated from ANTS/DPX-loaded liposomes
by Sephadex G75 column chromatography (Amersham Biosciences,
Uppsala, Sweden).
2.3. Coupling of the polymer
Three different polymers (CS-TGA77, CS-TGA150 and CS-TGA150-
MNA) were coupled to the liposomal surface by covalent bond forma-
tion between maleimide groups of the liposome and free SH-groups
of the polymer, as described previously [7] (see Fig. 1). Brieﬂy, the
polymer was dissolved in deionized water in a concentration of
2 mg/mL, of which an appropriate amount was added to the pre
formed liposomes and incubated overnight under agitation. The
molar ratio of SH-groups to maleimide groups was approximately
4:1, whereby a ﬁnal lipid concentration of 1.7 mg/mL and a polymer
concentration of 1.7 mg/mL were maintained throughout the study.
Uncoated liposomes were diluted with deionized water to the same
lipid concentration.
2.4. Particle characterization
2.4.1. Particle size
Size measurements were performed at room temperature by dy-
namic light scattering (DLS) using a Zetasizer 3000HS (Malvern In-
struments, Herrenburg, Germany). Coated- and uncoated liposomes
were measured after being diluted to a ﬁnal lipid concentration of
about 0.03 mg/mL with ultra-pure water (USF ELGA, High Wycombe
Bucks, UK). Particle size was analyzed by calculating the auto correla-
tion function of the detected intensity. The polydispersity index of the
liposomal suspension is given by the width of the size distribution.
2.4.2. Zeta potential
Zeta potentials of coated- and uncoated liposomes were deter-
mined with a Zetasizer nano ZS (Malvern Instruments, Herrenberg,
Germany) after dilution to a lipid concentration of 0.3 mg/mL with
a buffer containing 10 mM Tris and 2 mM CsCl, pH 7.0. All measure-
ments were carried out at room temperature.
2.5. Release study
Leakage and stability studies were carried out using uncoated- and
CS-TGA77-coated liposomes. All stability and release measurements
were carried out by measuring the ﬂuorescence of the suspension
(excitation wavelength: 360 nm; emission wavelength: 530 nm) after
diluting them with PBS buffer to a ﬁnal lipid concentration of approxi-
mately 50 μg/mL using a SPEX FLUOROMAX-3 ﬂuorescence spectrome-
ter (Jobin Yvon Horiba, Longjumeau Cedex, France). Leakage of ANTS/
DPX leads to an enhanced ﬂuorescence signal due to the greater
distance between ﬂuorophore and quencher. To determine the ﬂuo-
rescence intensity corresponding to 100% release of ANTS/DPX, 10 μL
of 10% Triton X-100™ were added to the cuvette (2 mL) before
measuring.
2.5.1. Long term storage stability
For long term storage stability, ANTS/DPX-loaded liposomes were
stored at 4 °C in darkness and aliquots were measured at different
time points over a time interval of 2 weeks.
2.5.2. Stability and release behavior in different simulated body ﬂuids
To measure the release kinetics in different body ﬂuids, freshly
prepared coated- and uncoated liposomes were exposed to either
simulated gastric ﬂuid (SGF; 1 L contains 2 g sodium chloride, 3.2 g
pepsin, 7 mL hydrochloric acid; pH 1.2) or simulated intestinal ﬂuid
(SIF; 1 L contains 6.8 g monobasic potassium phosphate, 10 g pancre-
atin, 77 mL 0.2 N sodium hydroxide; pH 6.8), which were prepared
Fig. 1. Reaction scheme for the covalent coupling of chitosan-TGA or the preactivated chitosan-TGA-MNA to a maleimide-functionalized phospholipid forming a stable thioether bond.
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with one of these ﬂuids and incubated for 24 h. At ﬁxed time points,
60 μL of these mixtures were withdrawn, mixed with 2 mL of PBS and
measured ﬂuorimetrically as described above.
2.6. Immunogenicity screening
2.6.1. Immunization of mice
Female BALB/cmice (Charles River Laboratories, Sulzfeld, Germany),
aged 8 weeks, were treated according to European Community rules of
animal care with the permission of the Austrian Ministry of Science
(BMWF-66.009/0172-II/3b/2011). Mice (n=8)were immunized orally
with CS-TGA77-coated liposomes (100 μL /gavage) or stayed naïve. Im-
munizations were performed on day 7/8, 21/22, 35/36 and 49/50 and
blood was drawn on day 0, 14, 28, 42, 56 and 70.
2.6.2. Detection of serum total immunoglobulins by ELISA
Antibody detection of total IgG, IgM, IgA or IgE was performed by
sandwich ELISA as described previously [14] with modiﬁcations. Brieﬂy,
microtiter plates (Maxisorp, Nunc, Roskilde, Denmark)were coatedwith
rat anti-mouse antibodies to IgE, IgMor IgA (BDPharmingen, Schwechat,
Austria; all 500 ng/mL in Na-bicarbonate puffer, pH 8.3) or rat anti-
mouse IgG (Bethyl Laboratories, Montgomery, USA; 2000 ng/mL).
Mouse isotype standard IgG, IgM, IgA and IgE (BD Pharmingen,
Schwechat, Austria)were used for dilution series (starting concentration
25 ng/mL for IgE and 100 ng/mL for IgM, IgA and IgG; further dilution
steps 1:2 (v/v)). Mouse sera were diluted 1:20 (v/v) for IgE, 1:5000 for
IgM and IgA and 1:10000 for IgG detection. Peroxidase-labeled anti-
mouse antibodies (Bethyl Laboratories, Montgomery, USA) were used
at a dilution of 1:10000 (v/v). Detection was performed with tetra-
methylbenzidine solution (BDBioscience, Vienna, Austria) andmeasure-
ment done at 450–630 nm.
2.6.3. Intradermal skin tests
Evans blue (100 μL of 5 mg/mL NaCl 0.9%; Merck, Darmstadt,
Germany) was injected into the tail vein of immunized mice on day
70. Subsequently, 30 μL of coated liposomes (50 μg lipid/mL PBS);
30 μL of codﬁsh extract (50 μg/mL PBS) as irrelevant control allergen;
mast cell degranulation compound 48/80 (20 μg/mL PBS; Sigma,
Steinheim, Germany) as positive control; and PBS as negative control
were administered intradermally. Reactions were evaluated as previ-
ously described [14].2.6.4. Isolation of splenocytes and evaluation of cytokines in stimulated
spleen cells
Spleen cell suspensions were stimulated as described previously
[14]. For stimulation, medium or irrelevant antigen codﬁsh extract
(400 μg/mL) as negative controls, Con A (5 μg/mL) as positive control,
or CS-TGA77-coated liposomes (lipid concentration: 10 μg/mL) were
added. Mouse IL-1α, IL-2, IL-4, IL-5, IL-6, IL-10, IL-13, IL-17A, IL-21,
IL-22, IL-27, IFN-γ and TNF-αwere measured in supernatants of stim-
ulated splenocytes by a multiplex immunoassay and analyzed on a
ﬂow cytometer (eBioscience, Vienna, Austria) according to the
manufacturer's instructions.
2.7. Ex vivo evaluation of permeation enhancing properties
For permeation studies, 200–300 g non-fasting male Sprague–
Dawley rats were sacriﬁced and their small intestine (jejunum, ileum)
removed immediately, preserved in 0.9%NaCl solution (w/v). The intes-
tine was cut into strips of about 1.5 cm, opened longitudinally and
rinsed free of luminal contents with freshly prepared medium
(138 mM NaCl, 1 mM MgSO4, 5 mM KCl, 10 mM glucose and 2 mM
CaCl2 buffered with 10 mM Hepes; pH 6.8). Subsequently, the tissues
were mounted in Ussing-type chambers with a permeation area of
0.64 cm2. The chambers were placed in a water bath preheated to
37 °C and immediately ﬁlled with 1 mL medium in the basolateral
compartment (BL), and 900 μL liposomal suspension (lipid concentra-
tion: 1.7 mg/mL; polymer concentration in case of coated liposomes:
1.7 mg/mL) mixed with 100 μL of a 1% FD4 solution in the apical com-
partment (AP). To determine the permeation in absence of any formu-
lation, an FD4 solution in a ﬁnal concentration of 0.1% (v/v) was used as
control. Over an incubation period of 3 h, 100 μL aliquots were with-
drawn every 30 min from the basolateral chamber and replaced by
100 μL of preheated medium. The amounts of permeated marker were
analyzed by ﬂuorescence spectroscopy at an excitation wavelength of
485 nm and an emission wavelength of 535 nm using a plate reader
(Tecan Austria GmbH, Austria). Cumulative corrections were made for
previously removed samples. Apparent permeability coefﬁcients (Papp;
cm/s) for FD4 were calculated according to the following equation:
Papp ¼
Q
A  c  t
whereQ is the amount of marker permeatedwithin 3 h (μg), A is the dif-
fusion area of the Ussing-type chamber (0.64 cm2), c is the initial
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time of the experiment (10,800 s). Transport enhancement ratios (ER)
were calculated by:
ER ¼ Papp sampleð Þ
Papp controlð Þ
2.7.1. Determination of the transepithelial electric resistance (TEER)
EVOM® (World Precision Instruments, Germany) connected to a
pair of adjacent electrodes was used to monitor the TEER of the intes-
tinal tissues throughout the experiment. Measurements were per-
formed at the beginning of the study to guarantee the integrity of
intestinal tissue, and after 60, 120 and 180 min to observe the effect
of the different liposomal formulations. The TEER measured prior to
each experiment was set as 100%, and all other values were calculated
in relation to this value.
2.8. Ex vivo evaluation of P-glycoprotein inhibitory properties
To study the permeation of rhodamine-123 (Rho-123), the distal
part of rat small intestine was used, since more efﬂux pumps are
present in this area [15,16]. Rho-123 is a well-known P-gp substrate
used for testing efﬂux pump activity [12,17,18]. Identical to perme-
ation enhancement studies, freshly excised tissues were mounted
on Ussing-type chambers. To conﬁrm the presence of P-gp on the in-
testinal tissues, chambers containing a 0.001% Rho-123 solution in
the apical compartment and 1 mL medium (138 mM NaCl, 1 mM
MgSO4, 5 mM KCl, 10 mM glucose and 2 mM CaCl2 buffered with
10 mM Hepes; pH 6.8) in the basolateral compartment were placed
in the incubator (37 °C) and the refrigerator (4 °C). As efﬂux pumps
are energy-dependent active transporters, their activity is lower at
4 °C [19,20] and an increased permeation of the P-gp substrate at
4 °C indicates the expression of P-gp. Positively evaluated, the tissues
could be used to determine efﬂux pump inhibitory properties.
Then we investigated the transport of Rho-123 in presence of differ-
ent liposomal suspensions (uncoated liposomes, CS-TGA-coated lipo-
somes of 77 and 150 kDa, and CS-TGA-MNA-coated liposomes). 1 mL
medium was added to the basolateral compartment, and 900 μL sam-
ples mixed with 100 μL of a 0.01% Rho-123 solution were added to
the apical compartment. Over a period of 3 h, 100 μL aliquots were
withdrawn at different time points from the basolateral compartment
and replaced immediately by the same volume of preheated medium.
The amounts of transported Rho-123 were analyzed by ﬂuorescence
spectroscopy (λex=488 nm and λem=525 nm) and Papp values for
Rho-123 as well as transport enhancement ratios were calculated
according to the equations described for the permeation of FD4.
In a second approachwe aimed to compare the absorptive (AP to BL)
with the secretory (BL to AP) transport of Rho-123 with and without
thiomer-coated liposomes. For this reason we monitored the perme-
ation of Rho-123 alone, in presence of verapamil as a potent inhibitor
of P-gp [21] (100 μMapical), in presence of CS-TGA150-MNA-coated li-
posomes (apical; in the same concentration as for the studies men-
tioned above) and in presence of both, verapamil and CS-TGA150-
MNA-coated liposomes. The efﬂux ratio was calculated by dividing theTable 1
Composition of all liposomal suspensions used within this study and characterization conce
posome (means±SD; n≥3).
Sample description Lipid composition a Added polymer b
Uncoated liposomes DPPC/DPPE-MCC –
CS-TGA77-coated liposomes DPPC/DPPE-MCC CS-TGA, 77kD
CS-TGA150-coated liposomes DPPC/DPPE-MCC CS-TGA, 150kD
CS-TGA150-MNA-coated liposomes DPPC/DPPE-MCC CS-TGA-MNA, 15
a The molar ratio of DPPC to DPPE-MCC was in all cases 3:0.3.
b A polymer to lipid weight ratio of 1:1 was used for all formulations.secretory Papp by the absorptive Papp. Additionally, the TEER was moni-
tored for absorptive transport studies, as described for permeation
enhancement studies.
2.9. Statistical analysis
All values are expressed as means±standard deviation (SD). Sta-
tistical data analyses were performed using the Student's t-test with
p≤0.05 as the minimal level of signiﬁcance, p≤0.01 for very signiﬁ-
cant and p≤0.001 for highly signiﬁcant. All tests were performed
using the statistical and process management software MINITAB 13.0.
3. Results and discussions
3.1. Characterization of thiolated liposomes
When thiomers are coupled to functionalized liposomes, covalent
bonds are formed between free SH-groups of the polymer and
maleimide groups on the surface of liposomes. A molar ratio of approx-
imately 4:1 (SH-groups:maleimide groups)was chosen for the coupling
reaction, since at this ratio the whole surface of liposomes is covered
with polymer [7].
After coupling, the particles showed an increase in size and a
wider size distribution, most probably due to a crosslinking of lipo-
somes by single polymer chains and an entanglement of the latter
[7,22]. Accordingly, liposomes coated with the higher molecular
mass CS-TGA150 or CS-TGA150-MNA were bigger and more hetero-
geneous than CS-TGA77-coated ones (the corresponding values are
listed in Table 1). However, oral delivery is not restricted according
to particle size. Similar to particle size, the zeta potential of liposomes
was also increased after coupling (see Table 1). Uncoated liposomes
display a negative zeta potential due to the negatively-charged phos-
phate group of the functionalized lipid. Thiolated chitosans them-
selves show a positive zeta potential and thus the overall surface
charge of thiomer-coated liposomes becomes positive. An increase
in zeta potential was also reported for the electrostatic binding of
positively ionized chitosan to the surface of negatively charged lipo-
somes [23–25]. In our study there was not much difference between
CS-TGA77-coated- and CS-TGA150-coated liposomes, whereas lipo-
somes coated with pre-activated CS-TGA (CS-TGA150-MNA) were
less positively charged due to the lesser amount of free SH-groups
in the sample.
3.2. Stability testing and release behavior
In order to study the stability and release proﬁles of uncoated- and
CS-TGA77-coated liposomes, the ANTS/DPX-model system was used,
consisting of the anionic ﬂuorophore ANTS and the cationic quencher
DPX. This test system was originally used to investigate the inﬂuence
of different agents on membrane stability [26], and was shown to be a
useful tool also for monitoring stability and drug release from lipo-
somes [7,27].
In principle, both the ﬂuorophore ANTS and the quencher mole-
cule DPX are encapsulated in liposomes during the hydration step.
The molecules are in close proximity to each other, and the shortrning their size, polydispersity and zeta potential after coupling the polymer to the li-
Size [nm] Polydispersity index Zeta potential [mV]
201.3±1.5 0.091±0.023 −32.68±1.99
354.5±3.4 0.213±0.036 28.90±1.45
590.2±18.9 0.629±0.155 35.85±3.19
0 kDa 702.6±138 0.738±0.264 8.62±1.36
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latter. Consequently, the monitored ﬂuorescence intensity is low,
though upon leakage and release of ANTS/DPX, the ﬂuorescence inten-
sity increases in a concentration-dependent manner. With this tech-
nique, the storage stability of coated- and uncoated liposomes as well
as release proﬁles in simulated gastric- and simulated intestinal ﬂuid
were monitored. Released ANTS/DPX was measured at ﬁxed time
points without separating the released ﬂuorophore.
Our liposome formulation is composed of saturated phospholipids
being in the gel phase at room temperature. In general, such formula-
tions containing high phase transition temperature lipids exhibit a
lower membrane permeability, and are less leaky than those formed
by unsaturated lipids [28]. Thus, the formulation was assumed to be
stable in PBS at 4 °C. Indeed, over a period of 14 days, neither the
uncoated nor the coated liposomes released more than 2% of the en-
capsulated compounds, and within this period, the liquid formulation
could for example be converted into a solid dosage form without ad-
ditional loss of encapsulated compounds. Uncoated liposomes were
stable also for the following 4 weeks, whereas a slow continuous re-
lease of ANTS/DPX from coated liposomes was recorded (data not
shown), leading to a 37% decrease of encapsulated compounds by
the end of this period.
To test the stability in different body ﬂuids, CS-TGA77-coated or
uncoated liposomes were mixed with either SGF or SIF and the leakage
measured by an increase in ﬂuorescence intensity was estimated over
24 h, as seen in Fig. 2. The stability of both liposomal suspensions in
the gastric environment was very high, and the release was in no case
more than 6%. Both formulations can therefore be considered stable in
the gastric environment.Whenmixing the particles with SIF containing
pancreatin as an enzyme mixture simulating the environment in the
small intestine, a slow release from coated and uncoated liposomes
could bemonitored over 24 h. Nevertheless, the release in the intestinal
environment was slower for thiomer-coated liposomes compared to
uncoated ones. As it was shown for membrane bound aminopeptidase
[11], thiomers exhibit enzyme-inhibitory properties. Accordingly they
might also inhibit lipid digesting enzymes in SIF, leading to a better per-
formance of thiomer-protected liposomes compared with uncoated
ones.
Even though the delivery system should release encapsulated drugs
once bound to the mucus, it has to be stable until there to prevent en-
capsulated drugs from degradation by gastrointestinal enzymes. This
is even more important if liposomes are loaded with sensitive drugs
like peptides or DNA-based drugs.Fig. 2. Release of ANTS/DPX at predetermined time points from uncoated DPPC/
DPPE-MCC liposomes (△,▲) and DPPC/DPPE-MCC liposomes coated with CS-TGA77
(4:1 molar ratio of SH-groups to maleimide groups) (○,●) in simulated gastric ﬂuid
(open symbols) and simulated intestinal ﬂuid (ﬁlled symbols). Indicated values are
the means±SD of at least three experiments.3.3. Immunogenicity screening
As liposomal formulations may induce immunogenic reactions [29],
we evaluated potential immunostimulatory effects of orally delivered
thiochitosan-coated liposomes by investigating their potency to affect
total antibody levels in mice in a sandwich ELISA assay. No effects on
total antibody levels of IgA, IgM, IgG and IgE could be detected in sera
of treated or naïve mice. These results already suggested that none of
the anaphylactogenic antibody isotypes in mice (IgE, IgG1) were
formed. Still, to rule out the residual likelihood for speciﬁc sensitization
as a side effect of oral gavages, type I skin tests were performed. The re-
sults showed thatmice immunizedwith thiochitosan-coated liposomes
or naïve mice showed no type I skin reaction to any of the test sub-
stances and reacted singularly to the positive control 48/80. Therefore,
oral gavages of the CS-TGA77-liposomes did not affect Th2 immunity
or induce speciﬁc sensitization in this mouse model. To capture any
other potential immunomodulatory effects of thiochitosan-coated lipo-
somes, a broad panel of cytokines derived from stimulated splenocytes
of the two groups of mice were analyzed. Isolated splenocytes of mice
immunized with CS-TGA77-coated liposomes or of naïve mice were
stimulated with medium, CS-TGA77-liposomes, irrelevant antigen cod-
ﬁsh extract or positive control Con A. Analysis of cytokines in multiplex
analysis in FACS showed that levels of cytokines were not elevatedwith
CS-TGA77-liposome-stimulation above medium or codﬁsh control in
splenocytes of mice immunized with CS-TGA77-liposomes or in naïve
mice. Collectively, no increase in total antibody levels of IgM, IgA, IgE
or IgG in sera of these mice were observed, nor was a reaction in intra-
dermal skin tests or an induction of cytokines (Th1/Th2/Th17/Th22).
Therefore, from the viewpoint of the immunological parameters, we
suggest that thiomer-coated liposomes are suitable carriers for the
oral application.
3.4. Ex vivo evaluation of permeation enhancing properties
The potential of CS-TGA77-coated liposomes as permeation en-
hancers was investigated by monitoring the transport of FD4 through
rat small intestine. We consider the test system advantageous over
the Caco-2 cell model, as the mucus layer is still present on the luminal
side of the tissue. Caco-2 cells, which are vastly used for testing the in-
testinal absorption, do not secrete any mucus — a fact which might in-
ﬂuence the rate of diffusion from the apical to the basolateral
compartment. Accordingly, freshly excised small intestine is much clos-
er to the situation in vivo than the well-established Caco-2 monolayer.
The absorptive transport of FD4 was investigated over a time period
of 3 h in the presence or absence of uncoated liposomes, or CS-
TGA77-coated liposomes. FD4 was selected as a marker molecule to
mimic the paracellular transport of hydrophilic macromolecules. All re-
sults displaying the cumulative transport of FD4 are illustrated in Fig. 3.
The resulting Papp values and enhancement ratios are shown in Table 2.
In the presence of uncoated liposomes, the permeation of FD4 was
slightly higher than observed for the model drug itself, as reﬂected by
an enhancement ratio of 1.9. This could be due to the presence of free
maleimide groups on the liposomal surface, which may interact with
SH-groups within the mucosa and thereby promote permeation of the
marker. However, using CS-TGA77-coated liposomes, the permeation
enhancing effect was increased to a ratio of 2.8.
The mechanism of permeation enhancing caused by thiomers was
described previously [30]. Crucial for this effect is the protein tyrosine
phosphatase (PTP), which is responsible for the dephosphorylation of
tyrosine subunits on tight junctions, resulting in a closing of the latter.
Consequently, an inhibition of PTP leads to a phosphorylated subunit
and therefore an opening of tight junctions. As PTP shows a cysteine
moiety as active site being responsible for its activation, reduced
glutathione (GSH) is capable of inhibiting the activity of PTP by a di-
sulﬁde bond formation [31]. However, GSH is rapidly oxidized on the
cell surface and so loses its ability to inhibit the activity of PTP [32].
Fig. 3. Absorptive permeation studies of FD4 across rat intestinal mucosa. Effect of
uncoated liposomes (△) and liposomes coated with the thiolated chitosans CS-TGA77
(●), CS-TGA150 (■), the S-protected chitosan CS-TGA150-MNA (♦) in comparison with
the FD4 control (×). Indicated values are the means±SD of at least three experiments.
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(GSSG) to GSH, as highlighted in previous studies [9,33]. To explain
the permeation enhancing properties of thiomer-coated liposomes the
following situation is expected to happen in vivo: Thiomer-coated lipo-
somes are bound to the mucosa of the small intestine due to their high
mucoadhesive properties [7], and therefore their concentration in-
creases sufﬁciently to ‘shift’ the balance between GSSG and GSH in the
direction of GSH, leading to an opening of tight junctions and therefore
an enhanced permeation of associated compounds. To investigate if the
permeation enhancement ratio of 2.8 measured for TGA-77-coated li-
posomes could be further improved, the suitability of other thiolated
chitosans as coating materials was also tested, utilizing CS-TGA150 —
the same polymer as CS-TGA77, only with a molecular weight of
150 kDa compared to 77 kDa to allow for examination of potential mo-
lecular weight inﬂuences. As the problem of SH-group oxidation was al-
ready mentioned, we sought to also test the S-protected thiomer
CS-TGA150-MNA in which some of the free SH-groups are protected
from oxidation by linking them to mercaptonicotinamide. We observed
only a small difference in the permeation enhancement between
CS-TGA77 and CS-TGA150; indicating that the permeation enhancing
properties do not strictly depend on the molecular weight of the
polymeric backbone. On the contrary, liposomes coated with
CS-TGA150-MNA resulted in a 4.1-fold increase in the permeation of
model substance FD4, representing a 1.3-fold increase in permeation en-
hancement when compared with liposomes coated with the corre-
sponding conventional thiomer (CS-TGA150), and a 2.2-fold increase
when compared with uncoated liposomes. Interestingly, this valueTable 2
Comparison of Papp values of uncoated liposomes, chitosan-TGA77-coated liposomes, chitos
ment ratios result from the comparison of each test solution with the corresponding cont
(*pb0.05, **pb0.01 and ***pb0.001 compared with each buffer control). Additionally the
TEER and the merit index, which is deﬁned as the ratio of the increase in Papp to the decrea
Substrate Test compound Papp×10−6 [cm/s]
FD4 Buffer 37 °C 1.98±0.36
Uncoated liposomes 3.79±0.64
CS-TGA77-coated liposomes 5.45±0.47
CS-TGA150-coated liposomes 6.06±0.20
CS-TGA150-MNA-coated liposomes 8.07±0.73
Rho-123 Buffer 37 °C 1.89±0.06
Buffer 4 °C 2.65±0.03
Uncoated liposomes 2.95±0.22
CS-TGA77-coated liposomes 5.29±0.77
CS-TGA150-coated liposomes 6.42±0.82
CS-TGA150-MNA-coated liposomes 7.94±0.95was even higher than the one reported for the same thiomer in solution
[12]. Within this study, the polymer concentration in the apical com-
partment was 0.5%, whereas in our studies a concentration of 0.15%
has been used. The permeation enhancement ratio for FD4 published
by Duennhaupt et al. was 3.3 in comparison with the buffer control,
whereas a 4-fold enhancementwas achievedwith three times less poly-
mer being immobilized on liposomes. One reason for improved perme-
ation enhancement properties of liposomes coated with S-protected
thiochitosan compared to those coated with conventional thiochitosan
might be the protection of SH-groups from oxidation. Accordingly,
after binding to the mucus, more SH-groups are available for reducing
GSSG. In vivo, the higher mucoadhesive effect of S-protected thiomers
[12] also contributes to an increase in permeation enhancing properties.
More clearly, if more polymers are bound to themucus for an enhanced
period of time, more SH-groupswill be available to open tight junctions.
3.4.1. TEER-measurements
Measuring the TEER provides information concerning the integrity
of the tissue and the opening/closing of tight junctions. In parallel to
the permeation studies, TEER was measured before starting the ex-
periment to guarantee that no tissues were damaged by mounting
them on the Ussing-type chambers. To monitor the effect of the dif-
ferent formulations, measurements were repeated every hour and
after ﬁnishing the study (Fig. 4). In the absence of test compounds,
only a slight decrease in the TEER was measured over 3 h. The addition
of uncoated liposomes, CS-TGA77-coated liposomes, CS-TGA150-coated
liposomes and CS-TGA150-MNA-coated liposomes resulted in a reduc-
tion of the TEER, whereby the slightest decrease was detected for
uncoated liposomes and the highest decrease was measured for lipo-
somes coatedwith S-protected thiochitosan. Hence, all tested liposomal
formulations increased the permeation of FD4 and decreased the
TEER; indicating that the integrity of the tissue was affected. Song et
al. [34] discuss in their work using different permeation enhancers the
relationship between an enhanced permeability and a reduced TEER,
and argue that an increased permeation enhancement is often related
to a decrease in TEER, but the proportionality is not always the same.
Permeation enhancers with high proportionality indices (called “merit
indices”, which are deﬁned as the ratio between the fold increase in
Papp over the fold decrease in TEER) preferably increase the permeabil-
ity and have less tendency to reduce the membrane integrity, thus
would likely serve as efﬁcient and safe absorption enhancers in the
body. The merit indices of all three thiomer-coated liposomes are very
high compared with their investigated permeation enhancers [34],
and could therefore be consideredhighly suitable for in vivo application.
3.5. Ex vivo evaluation of P-glycoprotein inhibitory properties
P-gp is one of the most widely studied and most important efﬂux
pumps controlling the disposition of drugs. Many drugs are substratesan-TGA150-coated liposomes and chitosan-TGA150-MNA-coated liposomes. Enhance-
rol solution. Indicated values represent the means±SD of at least three experiments
effect of named test compounds was tested on the TEER. Table shows the decrease in
se in the TEER.
Fold increase in Papp Fold decrease in TEER Merit index
– – –
1.9* 1.2 1.5
2.8** 1.5 1.9
3.1*** 1.5 2.1
4.1*** 1.6 2.6
– – –
1.4 – –
1.6* – –
2.8* – –
3.4* – –
4.2* – –
Fig. 4. Decrease of the transepithelial electrical resistance (TEER) after adding uncoated
liposomes* (△) and liposomes coated with the thiolated chitosans CS-TGA77** (●),
CS-TGA150** (■) and the S-protected chitosan CS-TGA150-MNA** (♦) in comparison
with the FD4 control (×). Indicated values are the means±SD of at least three experi-
ments (*pb0.05, **pb0.01 compared with the FD4 control solution).
Fig. 5. Efﬂux pump inhibition studies of Rho-123 across rat intestinal mucosa. Effect of
uncoated liposomes (△) and liposomes coated with the thiolated chitosans CS-TGA77
(●), CS-TGA150 (■), the S-protected chitosan CS-TGA150-MNA (♦) in comparison
with the Rho-123 control at 4 °C (+) and 37 °C (×). Indicated values are the
means±SD of at least three experiments.
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of the cell. In order to increase the bioavailability of these kinds of drugs,
P-gp inhibiting compounds, like thiomers, have been developed.
To test the P-gp inhibitory properties of thiomer-coated liposomes
the absorptive transport of 0.001% (m/v) Rho-123 was determined
using Ussing type chambers. A classical indicator for efﬂux pumpmedi-
ated transport is the permeation rate of substrates from the AP to BL and
BL to AP direction. In a previous study, it was found that the Rho-123 ef-
ﬂux ratio (secretory Papp/absorptive Papp) was about 2.8— clearly iden-
tifying Rho-123 as a substrate for efﬂux pumps [10]. Within this study,
the inﬂuence of different coated- and uncoated liposomes on the ab-
sorptive transport of the P-gp substrate Rho-123 was investigated
over a time period of 3 h. The most promising formulation was then
used for bidirectional transport studies of Rho-123 in presence and ab-
sence of the P-gp inhibitor verapamil.
As an orientating experiment, the transport of Rho-123 across fresh-
ly excised rat intestine was determined at 4 °C and 37 °C. At 37 °C, the
transport of Rho-123 is a combination of an active, efﬂux pumpmediat-
ed transport and passive diffusion [21] whereas at 4 °C, the activity of
ATP hydrolysis is low and therefore the mechanism of drug efﬂux is
stopped [19,20]. To this end, the permeation of Rho-123 at 4 °C is not
inﬂuenced by efﬂux pumps, but is only the product of passive diffusion,
leading to a higher permeation of Rho-123 at 4 °C than at 37 °C. All
results obtained from these studies are summarized in Table 2 and
Fig. 5. In the presence of uncoated liposomes, the transport of Rho-
123 through the intestinal tissue was only slightly enhanced, as it was
also seen by permeation studies with FD4. Liposomes coated with
CS-TGA77 or CS-TGA150 showed a pronounced enhancement ratio of
the Papp of 2.8 and 3.4 fold, respectively. Unlike many other efﬂux
pump inhibiting substrates, which inhibit P-gp based on a competitive
inhibition or ATP-depletion [35], thiomers and therefore also thiomer-
coated liposomes are not taken up from the gut due to their highmolec-
ularweight [33]. The postulatedmechanism for thiomer-mediated P-gp
inhibition is on the contrary based on the interaction of thiol groups
with the channel-forming transmembrane domain of the efﬂux pump.
As two of the twelve transmembrane domains of P-gp also contain a
cysteine residue, thiomers were expected to form disulﬁde bridges
with one or both of these subunits, thereby blocking the allosteric
change of the pump essential for drug transport [36]. However, based
on our new data, the above mentioned mechanism has to be seen
with caution. Thiomer-coated liposomes are between 354.5±3.4 and
702.6±138 nm in their size, depending on the polymer used (see
Table 1). Due to this size, it is highly unlikely that the particles areable to interact with cysteine residues within the channel. It can there-
fore be concluded that the mechanisms leading to an enhanced efﬂux
pump inhibition are not yet fully understood and need to be further
investigated. Nevertheless, the results clearly indicate an efﬂux pump
inhibitory effect of thiomer-coated liposomes. Even though CS-TGA77-
and CS-TGA150-coated liposomes demonstrated good permeation en-
hancing properties, the best results were obtained for CS-TGA150-
MNA-coated liposomes, leading to an enhancement ratio of 4.2. Some
of the thiol groups in S-protected thiomers are coupled to thiolated
pyridyl substructures, leading to a higher reactive form of thiol groups
compared to alkyl thiols, whose thiol groups are not in the reactive
state at physiological conditions given that the pKa of alkyl thiols is in
the range of 8–10 [37]. Consequently, thiomers do not reach their full
delivery potential in cases where the pH is lower. In contrast to that,
S-protected thiolated chitosan reacts independently from the surround-
ing pH. For this reason, CS-TGA150-MNA-coated liposomes performed
better in this study than CS-TGA77 or CS-TGA150-coated liposomes,
where the SH-groups were not protected.
As thiomer-coated liposomes were shown to enhance the
paracellular route of absorption, it is likely that the permeation of
Rho-123 is also improved via this pathway. In order to evaluate if this
enhanced permeation is exclusively due to an opening of tight junc-
tions, or the combination of an opening of tight junction with an inhibi-
tion of P-gp – the latter beingwhatwe propose – bidirectional transport
studies were performed using CS-TGA150-MNA coated liposomes.
These liposomes were chosen on the basis of their performance in our
previous investigations, and were compared with the known P-gp in-
hibitor verapamil. All results are summarized in Table 3. We ﬁrst mon-
itored the absorptive Rho-123 transport with and without verapamil,
which revealed a reduced permeation in presence of verapamil; thus
validating the presence of efﬂux pumps on the tissue used for this
study. This was further conﬁrmed by showing that the transport of
Rho-123, without any further additives, from the basolateral to the api-
cal side of the tissue was higher than from the apical to the basolateral
side (efﬂux ratio: 3.3). When the same bidirectional experiment was
performed in presence of verapamil, the efﬂux ratio decreased to 1.6
— again validating the P-gp inhibitory effect of the drug, and the reliabil-
ity of the test system. Although no complete inhibition was achieved
under these conditions, which would be indicated by an efﬂux ratio of
1, the effect of verapamil was still very prominent.
When CS-TGA150-MNA-coated liposomes were added to the api-
cal compartment, the efﬂux ratio decreased to a value of 1.8, being in
the range of verapamil. If the enhanced permeation of Rho-123 was
Table 3
Comparison of the absorptive and secretory apparent permeability coefﬁcients (Papp) of Rho-123 and resulting efﬂux ratios in the presence of different test compounds. Indicated
values represent the means±SD of at least three experiments. Additionally the effect of named test compounds was tested on the TEER (AP to BL direction).
Substrate Test compound Absorptive (AP to BL)
Papp×10−6 [cm/s]
Secretory (BL to AP)
Papp×10−6 [cm/s]
Efﬂux ratio
(secretory Papp/absorptive Papp)
Fold decrease
in TEER
Rho-123 Buffer 1.86±0.78 6.22±2.07 3.3 –
Verapamil 100 μM (apical) 3.49±0.86 5.47±0.99 1.6 1.1
CS-TGA150-MNA-coated liposomes (apical) 2.77±0.24 5.01±0.74 1.8 1.5
CS-TGA150-MNA coated liposomes plus
verapamil 100 μM (apical)
3.54±0.51 3.58±1.66 1.0 1.6
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ation from BL to AP should be much higher than from AP to BL,
reﬂected by an efﬂux ratio in the range of 3 to 4, which was not the
case. Even though it is well known that different transporters are
present on the basolateral and apical side of the tissue of the small in-
testine aside from P-gp – and therefore the ﬁndings from all experi-
ments investigating bidirectional transport through the entire cross
section of the small intestine have to be viewed in light of this – our
results strongly support the hypothesis that thiomer-coated lipo-
somes do exhibit P-gp inhibitory properties. This data indeed corrob-
orates the ﬁndings of our study monitoring the effect of different
thiomer-coated liposomes only in the absorptive direction, and
show that the enhanced permeation of Rho-123 is most probably
due to a combination of permeation enhancing and efﬂux pump in-
hibitory properties.
4. Conclusion
Within this study, a delivery system was developed to demonstrate
high stability in the gastrointestinal environment and to provide a sus-
tainable release of encapsulated compounds in the small intestinal mi-
lieu. These thiomer-coated liposomes did not cause immunogenic
reactions inmice, and the thiomers,whichwere immobilized at the sur-
face of liposomes, showed strong permeation enhancing- and efﬂux
pump inhibitory properties.
Taken together, our results indicate a high potential of thiomer-
coated liposomes for the oral delivery of unstable and poorly absorbed
drug compounds within the harsh GI-environment.
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